Skip to main content
Sign In

Michael H. Allen, MD


Contact Info:

Bldg. 500, Level 2, Rm. E2308

Phone: 303-724-4983

Email:  Dr. Allen
Clinical/Research Interests:
Dr. Allen is interested in bipolar disorder, suicide, and emergency psychiatry.​

Psychiatry Residency, The Institute of Living, Hartford, CT, 1979-1983

Chief Resident, The Institute of Living, Hartford, CT, 1982-1983

Assistant Director, Psychiatric Emergency and Admitting Services, Bellevue Hospital, 1987-92

Founding Director, Comprehensive Psychiatric Emergency Program, Bellevue Hospital, 1992-98

Founding Director, Emergency Psychiatry Fellowship, N Y U School of Medicine, 1994-98

Associate Director, Behavioral Health Services, Denver Health Medical Center, 1998-01

Associate Medical Director, Access Behavioral Care/Colorado Access, 2000-01

Director, Inpatient Psychiatry, University of Colorado Hospital,  2001-04

Director, Emergency and Consultation Psychiatry, University of Colorado Hospital, 2004-08

Director of Research, University of Colorado Denver Depression Center, 2008-

Director of Psychiatry, University of Colorado Hospital, 2009-

What Do Consumers Say They Want and Need During a Psychiatric Emergency?  Allen MH, Caprenter D, Sheets J,  Miccio B and Ross R.  Journal of Practical Psychiatry 2003; 9:29-58.

Organization and Function of Academic Psychiatric Emergency Services.  Currier GC and Allen MH.  General Hospital Psychiatry 2003; 25:124-129.

Use of Restraints and Pharmacotherapy in Academic Psychiatric Emergency Services. Allen MH, Currier GC, Grogg A.  General Hospital Psychiatry 2003; 26(1):42-49.

Phenomenology of Rapid Cycling Bipolar Disorder:  Data from the First 500 Participants in the Systematic Treatment Enhancement Program for Bipolar Disorder.  Schneck CS, Miklowitz DJ, Calabrese JR., Allen MH, Thomas MR, Wisniewski SR, Miyahara  S, Shelton MD, Ketter TA, Goldberg JF, Bowden CL, and Sachs GS.  American Journal of Psychiatry 2004; 161:1902-1908.

Haloperidol plus promethazine for psychosis induced aggression.  Huf G, Alexander J, Allen MH Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD005146. DOI: 10.1002/14651858.CD005146.

Suicidal Ideation and Pharmacotherapy Among STEP-BD Patients. Goldberg JF, Allen  MH,  Miklowitz DJ, Bowden CL, Endick  CJ, Wisniewski S, Miyahara S, Chessick CA, Thase ME, Calabrese JR, Sagduyu K and Sachs GS.  Psychiatric Services 2005; 56:1534-1540.

Differences in Contributors to Suicidal Ideation between Suicide Attempters and Non-Attempters with Bipolar Disorder.  Allen MH, Chessick CA, Miklowitz DJ, Wisniewski SR, Miyahara S, Calabrese JR, Goldberg JF, Thomas MR, Bowden CL, Marangell L and Sachs GS.  Suicide and Life Threatening Behavior 2005; 35(6):671-680.

Expert Consensus Guideline Series: Treatment of Behavioral Emergencies 2005. Allen MH, Currier GW, Carpenter D, Ross R and Docherty JP.  Journal of Psychiatric Practice 2005;11(Supp 1):1-108. 

Clinical Policy:  Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department.  Lukens TW, Wolf SJ, Edlow JA, Shahabuddin S, Allen MH, Currier GW and Jagoda AS for the American College of Emergency Physicians Clinical Policies Subcommittee on Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department.  Annals of Emergency Medicine 2006; 47:79-99. 

Linear Relationship of Valproate Serum Concentration to Response and Optimal Serum Levels for Acute Mania.  Allen MH, Hirschfeld RMA, Wozniak PJ, Baker JD and Bowden CL. American Journal of Psychiatry 2006; 163(2):272-275.

 Different Effects of Antipsychotic Medications on Substance Abuse Treatment Patients with Co-occurring Psychotic and Substance Abuse Disorders. Stuyt EB, Sajbel TA and Allen MH.  American Journal on Addictions 2006; 15(2):166-173.

Are Antidepressants Associated with New-Onset Suicidality in Bipolar Disorder?  A Prospective Study of Participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).  Bauer MS, Wisniewski SR, Marangell LB, Chessick CA, Allen MH, Dennehy EB, Miklowitz DJ, Thase ME and Sachs GS for the STEP-BD Investigators.  Journal of Clinical Psychiatry 2006; 67:48-55.

Azapirones for Generalized Anxiety Disorder.  Chessick CA, Allen MH, Thase ME, Batista Miralha da Cunha ABC, Kapczinski FFK, de Lima MSML, dos Santos Souza JJSS.  Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD006115.  online article

Heisenberg in the ER:  Beneficial Observer Effect on Involuntary Intramuscular Injections in a Psychiatric Emergency Service.  Damsa C, Ikelheimer DM, Adam E, Maris SA, Andreoli A, Lazignac C and Allen MH.  General Hospital Psychiatry 2006; 28:431-433.

Prospective Predictors of Suicide and Suicide Attempts in 1556 Patients with Bipolar Disorders Followed for up to 2 Years.  Marangell LB, Bauer MS, Dennehy EB, Wisniewski SR, Allen MH, Miklowitz DJ, Oquendo MA, Frank E, Perlis RH, Martinez JM, Fagiolini A, Otto MW, Chessick CA, Zboyan HA, Miyahara S, Sachs G, Thase ME..  Bipolar Disorders 2006; 8:566-575.

Intramuscular Olanzapine in Patients with Borderline Personality Disorder: An Observational Study in an Emergency Room.  Damsa C, Adam E, De Gregorio F, Cailhol L, Lejeune J, Lazignac C, Allen MH. General Hospital Psychiatry 2007; 29(1):51-53.

Effectiveness of Adjunctive Antidepressant Treatment for Bipolar Depression.  Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, Friedman ES, Bowden CL, Fossey MD, Ostacher MD, Ketter TA, Patel J, Hauser P, Rapport D, Martinez JM, Allen MH, Miklowitz DJ, Otto MW, Dennehy EB and Thase ME.  New England Journal of Medicine 2007 Apr 26; 356(17):1711-22.

A Naturalistic Study of Consecutive Agitated Emergency Department Patients Treated with Intramuscular Olanzapine Prior to Consent. Damsa C, Adam E, De Gregorio F, Mihai A, Lejeune J, Andreoli A, Maris S, Lazignac C, Allen MH. American Journal of Psychiatry 2008 Apr; 165(4):535-6.

Case Control Analyses of the Impact of Pharmacotherapy on Prospectively Observed Suicide Attempts and Completed Suicides in Bipolar Disorder:  Findings from STEP-BD.  Marangell LB, Dennehy EB, Wisniewski SR, Bauer MS, Miyahara S, Allen MH, Martinez M, Rayan Al Jurdi R, and Thase ME.  Journal of Clinical Psychiatry 2008 Jun;69(6):916-22. 

Factors Associated with the Use of Physical Restraints for Agitated Patients in Psychiatric Emergency Rooms.  Coutinho ESF, Huf G, Allen MH and Adams CE.  General Hospital Psychiatry 2008 May-June; 30:263-268. 

The Functional Impact of Subsyndromal Depressive Symptoms in Bipolar Disorder: Data from STEP-BD.  Marangell LB, Dennehy EB, Miyahara S, Wisniewski SR, Bauer MS, Rapaport MH and Allen MH.   Journal of Affective Disorders 2009 Apr;114(1-3):58-67.

Haloperidol Plus Promethazine for Psychosis-induced Aggression.  Huf G, Alexander J, Allen MH and Raveendran NS.  Cochrane Database Systematic Reviews 2005;(1):CD005146. 

The Psychiatric Emergency Research Collaboration – 01 (PERC-01):  Methods and Implications for Quality Measures.  Boudreaux ED,  Allen MH, Claassen C, Currier GW, Bertman L, Glick R, Park J and Feifel D on behalf of the PERC.  General Hospital Psychiatry 31 (2009) 515–522

1U01MH088278-01  9/30/2009 – 9/29/2014    $656,266 (includes in-directs)

Principle Investigator: Edwin Boudreaux, Ph.D. University of Massachusetts, Worcester

“Emergency Department Suicide Screening and Intervention Trial (EDSSIT)”


D1050235  (Clinical Trial)   7/1/2009 – 6/30/2012            

Dainippon Sumitomo Pharma American, Inc.  $37,619

A randomized, 6-week, double-blind, placebo controlled, flexible-dose, parallel-group study of Lurasidone adjunctive to lithium or divalproex for the treatment of bipolar I depression


D1050236  (Clinical Trial)  7/1/2009 – 6/30/2012           

Dainippon Sumitomo Pharma American, Inc.   $39,123

A randomized, 6-week, double-blind, placebo controlled, fixed-flexible dose, parallel-group study of  Lurasidone for the treatment of bipolar I depression


D1050236  (Clinical Trial)  7/1/2009 – 6/30/2012           

Dainippon Sumitomo Pharma American, Inc.   $29,747

A 24--week, flexible-dose, open-label extension study of Lurasidone for the treatment of bipolar I depression


3151A1-3360-WW (Clinical Trial)  7/1/2009 – 6/30/2012 

Wyeth Research  $126,042

A multicenter, double-blind, placebo-controlled, randomized withdrawal, parallel-group study to evaluate the   efficacy and safety of 50 mg/day of DVS SR in adult outpatients with major depressive disorder     


3151A1-3362-WW (Clinical Trial) 7/1/2009 – 6/30/2012

Wyeth Research  $176,004

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 2 fixed doses (10 and 50 mg/day) of DVS SR in adult outpatients with major depressive disorder   


Nicotine Replacement for Agitation in Schizophrenia  
NARSAD Independent Investigator Award.  $100,000


Systematic Treatment Enhancement Program for Bipolar Disorder 

NIMH-DS-0098 $1,440,000.